Levels of 17?-hydroxysteroid dehydrogenase type 10 in cerebrospinal fluid of people with mild cognitive impairment and various types of dementias

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023752%3A_____%2F15%3A43914762" target="_blank" >RIV/00023752:_____/15:43914762 - isvavai.cz</a>

Výsledek na webu

<a href="http://content.iospress.com/articles/journal-of-alzheimers-disease/jad142898" target="_blank" >http://content.iospress.com/articles/journal-of-alzheimers-disease/jad142898</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3233/JAD-142898" target="_blank" >10.3233/JAD-142898</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Levels of 17?-hydroxysteroid dehydrogenase type 10 in cerebrospinal fluid of people with mild cognitive impairment and various types of dementias

Popis výsledku v původním jazyce

Background: Overexpression of the mitochondrial enzyme 17?-hydroxysteroid dehydrogenase type 10 (17?-HSD10, which is also known as the intracellular amyloid-? peptide (A?) binding protein) is observed in cortical or hippocampal regions of patients with Alzheimer's disease (AD). It appears that 17?-HSD10 may play a role in the pathogenesis of AD. Objective: We investigated the possibility that levels of 17?-HSD10 in cerebrospinal fluid could be a prospective biomarker of AD. Methods: We estimated the enzyme levels in 161 people (15 non-demented controls, 52 people with mild cognitive impairment (MCI), 35 people with probable AD, or 59 people with other types of dementia) and compared them with those of A?1 - 42, tau, and phospho-tau. Results: We found significantly higher levels of 17?-HSD10 in people with MCI due to AD (to 109.9% ), with AD (to 120.0% ), or with other types of dementia (to 110.9% ) when compared to the control group. The sensitivity of the new biomarker to AD was 80.0%

Název v anglickém jazyce

Levels of 17?-hydroxysteroid dehydrogenase type 10 in cerebrospinal fluid of people with mild cognitive impairment and various types of dementias

Popis výsledku anglicky

Background: Overexpression of the mitochondrial enzyme 17?-hydroxysteroid dehydrogenase type 10 (17?-HSD10, which is also known as the intracellular amyloid-? peptide (A?) binding protein) is observed in cortical or hippocampal regions of patients with Alzheimer's disease (AD). It appears that 17?-HSD10 may play a role in the pathogenesis of AD. Objective: We investigated the possibility that levels of 17?-HSD10 in cerebrospinal fluid could be a prospective biomarker of AD. Methods: We estimated the enzyme levels in 161 people (15 non-demented controls, 52 people with mild cognitive impairment (MCI), 35 people with probable AD, or 59 people with other types of dementia) and compared them with those of A?1 - 42, tau, and phospho-tau. Results: We found significantly higher levels of 17?-HSD10 in people with MCI due to AD (to 109.9% ), with AD (to 120.0% ), or with other types of dementia (to 110.9% ) when compared to the control group. The sensitivity of the new biomarker to AD was 80.0%

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FH - Neurologie, neurochirurgie, neurovědy

OECD FORD obor

—

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Alzheimer's Disease

ISSN

1387-2877

e-ISSN

—

Svazek periodika

48

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

10

Strana od-do

105-114

Kód UT WoS článku

000360931700010

EID výsledku v databázi Scopus

2-s2.0-84940995512